Analysts’ Top NA Picks: Rapport Therapeutics, Inc. (RAPP), SpaceX (SPCX)

Analysts reiterated Buy ratings on Rapport Therapeutics (RAPP) with a $82.00 target, SpaceX (SPCX) with a $300.00 target, and Infleqtion (INFQ) with a $25.00 target. RAPP's consensus target is $68.30, SPCX's is $221.03, and INFQ's is $20.67.

Original reporting
Published Oct 22, 2026, 10:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 12:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Analysts’ Top NA Picks: Rapport Therapeutics, Inc. (RAPP), SpaceX (SPCX) — source image
Decision brief

The 30-second read

$RAPPBullishMed
01

Why it matters

Analyst upgrades provide fresh catalysts that can move the stocks in the short term.

02

Market read

New analyst coverage creates short‑term trading opportunities for RAPP and INFQ.

03

What to watch

Potential dilution from future financing rounds could offset upside.

Relevance 5/10Novelty 5/10Timing: today

Background

The article aggregates fresh analyst recommendations for three companies, highlighting new price targets and buy ratings.

Company-level read

Ticker impact

$RAPPBullishHigh confidence
Context

Analyst Justin Walsh reiterated a Buy rating with a new $82 price target, indicating fresh bullish coverage.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Buy rating and $82 target represent a 125% upside from current price, prompting buying interest.

$INFQBullishMedium confidence
Context

BTIG analyst Jesse Sobelson maintained a Buy rating and set a $25 price target, raising the consensus outlook.

Expected impact

potential modest upside as the $25 target is nearly three times the current price

Evidence & confidence

The new target signals strong confidence, likely attracting short‑term buying.

Market effects

Healthcare and technology sectors may see modest uplift from analyst optimism.

U.S. markets could see slight positive bias in small‑cap biotech and tech stocks.

Limited to U.S. listed micro‑caps; no broad macro impact.

Counterpoint

Analyst targets may be overly optimistic given recent market volatility.

Key entities

  • Justin Walsh

    JonesTrading analyst covering Rapport Therapeutics.

  • Jesse Sobelson

    BTIG analyst covering Infleqtion.

Related articles

$INFQMed

What Infleqtion (INFQ) Said on Its Q3 Earnings Call

Infleqtion (INFQ) reported Q3 cash use of $16.3M, up from $6M YoY, with $560M in cash. It achieved a 2026 target of 30 entangled logical qubits early. RPO reached $51.2M, with computing commitments growing. NASA expanded a contract by $20M, and the company secured a $12M UK contract. Infleqtion expects $10M revenue from an Illinois project in 2027.

$INFQMedAI 8/10

Infleqtion Reports Third Quarter 2026 Record Revenue Results, Achieves 30-Logical-Qubit Milestone and Maintains Full-Year Revenue Guidance Third Quarter 2026…

Infleqtion, Inc. (INFQ) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Infleqtion Reports Third Quarter 2026 Record Revenue Results, Achieves 30-Logical-Qubit Milestone and Maintains Full-Year Revenue Guidance Third Quarter 2026 Financial Summary • Revenue: $9.1 million, up 25% year over year, nine-month revenue $32.6 million, up 57% ye